Audrey joined the Myeloma Crowd as the Community Manager in 2020 after previously working in the nonprofit field for 4 years as a director of Fundraising and Development. She graduated from BYU with a major in Spanish and Nonprofit Management. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Bob was diagnosed with myeloma unexpectedly in 2015 through a traumatic experience. After recovering and a failed SCT, he is working his way through other chemotherapy cocktails. Bob is extremely charismatic, loves his wife and family, and is a coach for the Myeloma Crowd if you would like to connect with him. He believes in the power of hope and is a Patient Advocate for our Selinexor Support Group.

Chrissy Degennaro is a true myeloma warrior. Diagnosed at 36 years old, only a year and a half after giving birth, her entire life was altered. After 2 stem cell transplants, 2 CAR T cell therapies, and 27 other chemo regimens, Chrissy was lacking options and ready to throw in the towel. However, after overcoming her hesitancies about the new drug selinexor (or XPOVIO), she has been continuing to fight for the last year. Chrissy is charismatic, family-oriented, and a wonderful Patient Advocate for our Selinexor Support Group.

Julie is from Cincinnati, OH and has over 30 years of oncology nursing experience. She has been a Nurse Liaison in the Multiple Myeloma therapeutic arena for the past 7 years. Some of her primary responsibilities include: Providing disease state educational presentations and on-label product presentations to nurses, physicians, & pharmacists. She also focuses on developing strong long-term relationships with clinical personnel, advanced practice provider opinion leaders, key nurse opinion leaders, advocacy organizations, key nursing organizations, and societies focused on the nursing segment. The most fulfilling part of her nursing role is her interactions with the patients at the support groups. She is impressed and inspired daily by their depth of knowledge particularly as it relates to the therapeutic regimens and ongoing clinical trials.